D. Frye

2.5k citations
22 papers · 1.9k · 2 hit papers · h-index 12

Impact in

  • Oncology top 2%
    • Cancer Treatment and Pharmacology
    • HER2/EGFR in Cancer Research
    • Colorectal Cancer Treatments and Studies
    • Neutropenia and Cancer Infections
    • Breast Cancer Treatment Studies

Papers in

    • Cancer Treatment and Pharmacology 17
    • Neutropenia and Cancer Infections 4
    • HER2/EGFR in Cancer Research 3
    • Cancer Diagnosis and Treatment 3
    • Breast Cancer Treatment Studies 12

D. Frye

22 papers receiving 1.9k citations

Hit Papers

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. 1996 · 596 citations
5960+11+23Years since publication200400600

Peers

D. Frye
Comparison fields: 5 of 96
  • Oncology 1.5k
  • Cancer Research 708
  • Dermatology 173
  • Pulmonary and Respiratory Medicine 401
  • Hematology 127
Replace G. N. Hortobágyi with:
G. N. Hortobágyi United States
Giuseppe Capri Italy
G. Catimel France
A. U. Buzdar United States
Cecilia Nisticò Italy
Gisele Sarosy United States
Debra Frye United States
Paola Papaldo Italy
Robert J. Belt United States
R. Theriault United States
D. Frye relative to G. N. Hortobágyi United States G. N. Hortobágyi's profile →
Citations per field
00.5×1.7×
G. N. Hortobágyi · 1×
Citations per year

Countries citing papers authored by D. Frye

Since Specialization
Citations

This map shows the geographic impact of D. Frye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Frye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Frye more than expected).

Fields of papers citing papers by D. Frye

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Frye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Frye. The network helps show where D. Frye may publish in the future.

Co-authors

The 25 scholars most cited alongside D. Frye, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with D. Frye Line = papers co-authored together D. Frye links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer
Hit paper breakdown →
1991615
2
Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.
Hit paper breakdown →
1996596
3 1989149
4 1997122
5 1987102
6 199698
7 200757
8
The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer.
199345
9
Capecitabine: nursing implications of a new oral chemotherapeutic agent.
199938
10 199828
11 199914
12 199411
13
Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
199710
14
Phase II study of iproplatin in metastatic breast carcinoma.
19879
15 19967
16 19915
17 19904
18 20044
19
Reutilization of doxorubicin in patients with progressive metastatic breast cancer
19893
20 20053

About D. Frye

D. Frye is a scholar working on Oncology, Cancer Research, Dermatology, Cardiology and Cardiovascular Medicine and Pathology and Forensic Medicine, having authored 22 papers that have together received 1.9k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (17 papers), Breast Cancer Treatment Studies (12 papers), Chemotherapy-related skin toxicity (5 papers), Neutropenia and Cancer Infections (4 papers), Chemotherapy-induced cardiotoxicity and mitigation (4 papers), HER2/EGFR in Cancer Research (3 papers), Cancer Diagnosis and Treatment (3 papers) and Lung Cancer Treatments and Mutations (2 papers). The work is most often cited by research in Oncology (1.5k citations), Cancer Research (708 citations), Dermatology (173 citations), Pulmonary and Respiratory Medicine (401 citations) and Hematology (127 citations). D. Frye has collaborated with scholars based in United States and United Kingdom. Frequent co-authors include Aman U. Buzdar, Gabriel N. Hortobágyi, Terry L. Smith, L. D. Ziegler, Frankie A. Holmes, A. U. Buzdar, G. N. Hortobágyi, R S Walters, R. Theriault and Martin N. Raber. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer, JNCI Journal of the National Cancer Institute and The Breast.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact